Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) for NDMM NTE

This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed

bortezomib
dexamethasone
  • 0 views
  • 31 Jul, 2021
  • 4 locations
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes

own to treat some blood cell cancers. Objectives To test the safety and efficacy of the drug combination of bortezomib and clofarabine.

lymphoma
bisphosphonate
primary cancer
solid tumour
chemotherapy regimen
  • 25 views
  • 23 Sep, 2022
  • 1 location
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

The phase 2 study evaluated the efficacy and safety of bortezomib in combination with lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients who receive

plasmacytoma
bone marrow procedure
remission
dexamethasone
neutrophil count
  • 0 views
  • 26 Jan, 2021
  • 1 location
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in

multiple myeloma
cancer
paresthesia
bortezomib
chemotherapy regimen
  • 2 views
  • 21 Apr, 2022
  • 1 location
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790)

Adult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be

  • 102 views
  • 24 Jul, 2022
  • 7 locations
High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study

a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.

  • 0 views
  • 25 Apr, 2022
  • 1 location
DARA RVD For High Risk SMM

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating

velcade
dexamethasone
Accepts healthy volunteers
bortezomib
anemia
  • 0 views
  • 30 Oct, 2021
  • 2 locations
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that

multiple myeloma
bone marrow plasma cells
calcium
monoclonal antibodies
nephropathy
  • 5 views
  • 30 Jun, 2022
  • 1 location
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

regimens between bortezomib-thalidomide-dexamethasone (BTD) and bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to provide more clinical evidence for the standard

immunoglobulin
thalidomide
cyclophosphamide
bortezomib
bone marrow procedure
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma

or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

immunoglobulin
dexamethasone
monoclonal antibody therapy
serum pregnancy test
immunomodulatory imide drug
  • 0 views
  • 22 Apr, 2022
  • 15 locations